Ceftriaxon MIP Pharma 2 g infuusiokuiva-aine, liuosta varten فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

ceftriaxon mip pharma 2 g infuusiokuiva-aine, liuosta varten

mip pharma gmbh - ceftriaxone sodium - infuusiokuiva-aine, liuosta varten - 2 g - keftriaksoni

Ganciclovir Oresund Pharma 500 mg kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

ganciclovir oresund pharma 500 mg kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos

oresund pharma aps - ganciclovir sodium - kuiva-aine välikonsentraatiksi infuusionestettä varten, liuos - 500 mg - gansikloviiri

Pelmeg الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

pelmeg

mundipharma corporation (ireland) limited - pegfilgrastiimia - neutropenia - immunostimulantit, - vähentää neutropenian kestoa ja kuumeisen neutropenian esiintyvyyden vuoksi kemoterapiaa.

Rivastigmine 3M Health Care Ltd الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

rivastigmine 3m health care ltd

3m health care limited - rivastigmiini - alzheimerin tauti - psychoanaleptics, , antikoliiniesteraasit - lievän tai kohtalaisen vaikean alzheimerin dementian oireellinen hoito.

TARGINIQ 2.5 mg / 1.25 mg depottabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

targiniq 2.5 mg / 1.25 mg depottabletti

mundipharma oy - naloxoni hydrochloridum dihydricum,oxycodoni hydrochloridum - depottabletti - 2.5 mg / 1.25 mg - oksikodoni ja naloksoni

Clopidogrel Viatris (previously Clopidogrel Taw Pharma) الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

clopidogrel viatris (previously clopidogrel taw pharma)

viatris limited - klopidogreelibesilata - peripheral vascular diseases; stroke; myocardial infarction - antitromboottiset aineet - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st-segmentin nousua akuutti sydäninfarkti, yhdessä asa lääketieteellisesti hoitoa saaneilla potilailla oikeutettu liuotushoito. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. lisätietoja, katso kohta 5.

Xyrem الاتحاد الأوروبي - الفنلندية - EMA (European Medicines Agency)

xyrem

ucb pharma ltd - natriumoksibaatti - cataplexy; narcolepsy - muut hermoston huumeet - narkolepsian hoito katapleksiaan aikuispotilailla.

OXYCONTIN 15 mg depottabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

oxycontin 15 mg depottabletti

mundipharma oy - oxycodoni hydrochloridum - depottabletti - 15 mg - oksikodoni

OXYCONTIN 30 mg depottabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

oxycontin 30 mg depottabletti

mundipharma oy - oxycodoni hydrochloridum - depottabletti - 30 mg - oksikodoni

OXYCONTIN 60 mg depottabletti فنلندا - الفنلندية - Fimea (Suomen lääkevirasto)

oxycontin 60 mg depottabletti

mundipharma oy - oxycodoni hydrochloridum - depottabletti - 60 mg - oksikodoni